Our ResourcesNews & Events

13th January 2020 | Press Releases

Prometic Bioseparations to become Astrea Bioseparations

Ballasalla, Isle of Man, British Isles and Cambridge, UK – January 13th, 2020 – Prometic Bioseparations Ltd announced today that it is changing its name to Astrea Bioseparations Ltd.

“This name change follows our divestment from Liminal Biosciences and demonstrates a re-focus on providing products and services that support the highest quality and purity for biotherapeutics. We chose ‘Astrea – the Goddess of Purity’ to reflect the capability of our ligand discovery platform by providing world leading affinity chromatography adsorbents for both recombinant proteins and Gene Therapy products.” said Dr. Steve Burton, CEO of Astrea.

“Astrea Bioseparations is the only bioseparations company that can provide ligand discovery, adsorbent development and scale up, large scale adsorbent manufacture (up to 1000L batches) and GMP pre-packed columns,” Dr. Burton added.

Along with the new name a new website has been launches, to find out more please visit www.astreabioseparations.com.

About Astrea Bioseparations Ltd.

Astrea Bioseparations Ltd. (formerly Prometic Bioseparations Ltd) (https://www.astreabioseparations.com/) is a bioseparations company specializing in the research, development, manufacture and marketing of bioseparation products including chromatography adsorbents and pre-packed chromatography columns. A wholly owned subsidiary of Gamma Biosciences, a KKR & Co. company, Astrea Bioseparations has R&D laboratories located at Cambridge, UK and manufacturing facilities located at the Isle of Man, British Isles and Joliette, Quebec, Canada.

For further information please contact:

Beth Willers
White Matter Communications